Evidence map›Paper›PMID 29851968›Full record

ArticlePLoS neglected tropical diseases2018

Zika virus infection in Nicaraguan households.

Raquel Burger-Calderon, Karla Gonzalez, Sergio Ojeda, José Victor Zambrana, Nery Sanchez, Cristhiam Cerpas Cruz, Harold Suazo Laguna, Fausto Bustos, Miguel Plazaola, Brenda Lopez Mercado and 10 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Raquel Burger-CalderonDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California, United States of America.
Karla GonzalezSustainable Sciences Institute, Managua, Nicaragua.
Sergio OjedaSustainable Sciences Institute, Managua, Nicaragua.
José Victor ZambranaSustainable Sciences Institute, Managua, Nicaragua.
Nery SanchezSustainable Sciences Institute, Managua, Nicaragua.
Cristhiam Cerpas CruzSustainable Sciences Institute, Managua, Nicaragua.
Harold Suazo LagunaSustainable Sciences Institute, Managua, Nicaragua.
Fausto BustosDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California, United States of America.
Miguel PlazaolaSustainable Sciences Institute, Managua, Nicaragua.
Brenda Lopez MercadoSustainable Sciences Institute, Managua, Nicaragua.
Douglas ElizondoSustainable Sciences Institute, Managua, Nicaragua.
Sonia ArguelloSustainable Sciences Institute, Managua, Nicaragua.
Jairo Carey MonterreySustainable Sciences Institute, Managua, Nicaragua.
Andrea NuñezSustainable Sciences Institute, Managua, Nicaragua.
Josefina ColomaDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California, United States of America.
Jesse J WaggonerDepartment of Medicine, Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, Georgia, United States of America.
Aubree GordonDepartment of Epidemiology, School of Public Health, University of Michigan, Michigan, United States of America.
Guillermina KuanCentro de Salud Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua.
Angel BalmasedaSustainable Sciences Institute, Managua, Nicaragua.
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California, United States of America.ORCID 0000-0002-7238-4037
Sustainable Sciences Institute · USNational Autonomous University of Nicaragua · NIUniversity of California, Berkeley · USEmory University · USMinisterio de Salud · NIUniversity of Michigan · US

Funding

T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Eva Harris · 2015 to 2026
$34.1M
Epidemiological, Clinical & Immunological Studies of Zika, dengue and chikungunyaR01AI099631 · NIAID · SUSTAINABLE SCIENCES INSTITUTE · PI BALMASEDA, ANGEL LAZARO · 2012 to 2021
$1.8M
NIAID NIH HHS P01 AI106695NIAID NIH HHS R01 AI099631NIH HHS P01AI106695NIH HHS R01AI099631
6 · The paper itself

Abstract

Zika virus (ZIKV) infection recently caused major epidemics in the Americas and is linked to congenital birth defects and Guillain-Barré Syndrome. A pilot study of ZIKV infection in Nicaraguan households was conducted from August 31 to October 21, 2016, in Managua, Nicaragua. We enrolled 33 laboratory-confirmed Zika index cases and their household members (109 contacts) and followed them on days 3-4, 6-7, 9-10, and 21, collecting serum/plasma, urine, and saliva specimens along with clinical, demographic, and socio-economic status information. Collected samples were processed by rRT-PCR to determine viral load (VL) and duration of detectable ZIKV RNA in human bodily fluids. At enrollment, 11 (10%) contacts were ZIKV rRT-PCR-positive and 23 (21%) were positive by IgM antibodies; 3 incident cases were detected during the study period. Twenty of 33 (61%) index households had contacts with ZIKV infection, with an average of 1.9 (range 1-6) positive contacts per household, and in 60% of these households, ≥50% of the members were positive for ZIKV infection. Analysis of clinical information allowed us to estimate the symptomatic to asymptomatic (S:A) ratio of 14:23 (1:1.6) among the contacts, finding 62% of the infections to be asymptomatic. The maximum number of days during which ZIKV RNA was detected was 7 days post-symptom onset in saliva and serum/plasma and 22 days in urine. Overall, VL levels in serum/plasma, saliva, and urine specimens were comparable, with means of 5.6, 5.3 and 4.5 log10 copies/ml respectively, with serum attaining the highest VL peak at 8.1 log10 copies/ml. Detecting ZIKV RNA in saliva over a similar time-period and level as in serum/plasma indicates that saliva could potentially serve as a more accessible diagnostic sample. Finding the majority of infections to be asymptomatic emphasizes the importance of silent ZIKV transmission and helps inform public health interventions in the region and globally.

Indexed as

AdolescentAdultAgedAsymptomatic DiseasesChildChild, PreschoolCongenital AbnormalitiesFamily CharacteristicsFemaleGuillain-Barre SyndromeHumansInfantMaleMiddle AgedNicaraguaPilot ProjectsRNA, Viral

Identifiers

PMID29851968
PMCPMC6014677
OpenAlexW2807522427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.